AP2001002167A0 - Use of 17-ketosteroids for the treatment of toxoplasmosis and crytosporidiosis - Google Patents

Use of 17-ketosteroids for the treatment of toxoplasmosis and crytosporidiosis

Info

Publication number
AP2001002167A0
AP2001002167A0 APAP/P/2001/002167A AP2001002167A AP2001002167A0 AP 2001002167 A0 AP2001002167 A0 AP 2001002167A0 AP 2001002167 A AP2001002167 A AP 2001002167A AP 2001002167 A0 AP2001002167 A0 AP 2001002167A0
Authority
AP
ARIPO
Prior art keywords
compounds
treatment
toxoplasmosis
crytosporidiosis
ketosteroids
Prior art date
Application number
APAP/P/2001/002167A
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T Prendergast
Krupakar Prendergast THADIKONDA
Original Assignee
Hollis Eden Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals filed Critical Hollis Eden Pharmaceuticals
Publication of AP2001002167A0 publication Critical patent/AP2001002167A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides the use of 17-ketosteroid compounds, e.g., 16alpha-bromoepiandrosterone, as well as derivatives, metabolites and precursors of such compounds, and pharmaceutically acceptable salts of any of these compounds, collectively defined herein as the "compounds of the present invention", to treat or prevent Toxoplasmosis or Cryptosporidiosis in patients in need of such treatment or prophylaxis. the fromula (1) compounds can also be used to emeliorate or reduce one or more symptoms associated with such infections.
APAP/P/2001/002167A 1998-11-27 1999-11-24 Use of 17-ketosteroids for the treatment of toxoplasmosis and crytosporidiosis AP2001002167A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11012798P 1998-11-27 1998-11-27
US12408799P 1999-03-11 1999-03-11
US12605699P 1999-03-23 1999-03-23
PCT/US1999/028080 WO2000032176A2 (en) 1998-11-27 1999-11-24 Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis

Publications (1)

Publication Number Publication Date
AP2001002167A0 true AP2001002167A0 (en) 2001-06-30

Family

ID=27380789

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002167A AP2001002167A0 (en) 1998-11-27 1999-11-24 Use of 17-ketosteroids for the treatment of toxoplasmosis and crytosporidiosis

Country Status (4)

Country Link
AP (1) AP2001002167A0 (en)
AU (1) AU1923500A (en)
CA (1) CA2352387A1 (en)
WO (1) WO2000032176A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
PT1955700E (en) 1999-09-30 2011-05-04 Harbor Biosciences Inc Therapeutic treatment of androgen receptor driven conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (en) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Pharmaceutical preparation suitable for the prophylaxis or therapy of a retroviral infection or a complication or consequence thereof.
WO1997038695A1 (en) * 1996-04-17 1997-10-23 Prendergast Patrick T Dhea combination therapy
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors

Also Published As

Publication number Publication date
WO2000032176A2 (en) 2000-06-08
CA2352387A1 (en) 2000-06-08
AU1923500A (en) 2000-06-19
WO2000032176A3 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
MY133027A (en) C-4"-substituted macrolide derivatives
PT804252E (en) METALLIC CHELTER AGENTS THAT CONTAINS DIAMOND MONOAMINES AND THIOIS
PL309348A1 (en) Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries
CA2292359A1 (en) Novel azalides and methods of making same
BG104644A (en) Novel macrolides
GR3022459T3 (en) Quinuclidine derivative as substance p antagonist.
PA8486001A1 (en) CELECOXIB COMPOSITIONS
MX9707980A (en) 4-aminoquinazoline derivatives.
IL111077A0 (en) Pharmacologically active pyridine derivatives and processes for the preparation thereof
PL309594A1 (en) Apllication of rilusole in treating parkinson disease and parkinsonian syndromes
UA41355C2 (en) Agent for treating neuro-aids
BG105534A (en) 5ht1 means and method for the treatment of migraine
ATE344269T1 (en) CARBAMAT AND CARBAZATE KETOLIDE ANTIBIOTICS
AP2001002142A0 (en) 13-membered azalides and their use as antibiotic agents.
GR3024157T3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy.
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
AP2001002167A0 (en) Use of 17-ketosteroids for the treatment of toxoplasmosis and crytosporidiosis
GR3031967T3 (en) Ocular compositions containing steroids and their use in treating glaucoma
HUT73231A (en) Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis
GR3034142T3 (en) Composition for the treatment or prevention of herpes
AU4944899A (en) New pharmaceutically active compounds
YU64300A (en) 2"-deoxy hygromycin derivatives
MX9701606A (en) Combination therapy to prevent bone loss- progesterone and strogen.
ZA9427B (en) Use of riluzole for promoting restoration following radiation
GB9926301D0 (en) Novel compounds